Differin Lotion .1
Mechanism of Action
Adapalene binds to specific retinoic acid nuclear receptors but does not bind to cytosolic receptor protein. Biochemical and pharmacological profile studies have demonstrated that adapalene is a modulator of cellular differentiation, keratinization and inflammatory processes. However, the significance of these findings with regard to the mechanism of action of adapalene for the treatment of acne is unknown.
Pharmacodynamics of DIFFERIN Lotion is unknown.
Systemic exposure of adapalene following a topical application of DIFFERIN Lotion was studied in two pharmacokinetic (PK) clinical trials. The first trial was conducted in 14 adult subjects 18 to 29 years of age with severe acne and the second trial was conducted in 13 adolescent subjects 12 to 17 years of age with moderate to severe acne.
In each trial, subjects were treated with 2 g of DIFFERIN Lotion applied once daily to approximately 1000 cm² of acne involved skin for 28 days (adolescent subjects) or 30 days (adult subjects). Serial plasma samples were collected at 24 or 72 hours following application on days 1, 15 and 28/30.
Daily topical application of DIFFERIN Lotion resulted in low systemic exposure to adapalene in the two populations (adult and adolescent subjects).
In the adult population, all plasma concentrations in 12 out of 14 subjects were below the limit of quantification (LOQ=0.1 ng/mL). One subject had one sample above LOQ at day 30 and the other subject had four plasma samples above LOQ on both days 1 and 15, which ranged from 0.102 and 0.131 ng/mL.
In the adolescent population, plasma concentrations were quantifiable ( > 0.1 ng/mL) in five subjects. On Day 28, the mean Cmax was 0.128 ± 0.049 ng/mL (range: < 0.100 to 0.244 ng/mL) and the mean of AUC0-24hr was 3.07 ± 1.21 ng.hr/mL (range: 1.86 to 4.93 ng.hr/mL). Adapalene plasma concentrations in all subjects were below the limit of quantification ( < 0.1 ng/mL) 48 hours after the last application on Day 28.
The safety and efficacy of DIFFERIN Lotion applied once daily for the treatment of acne vulgaris were assessed in two 12-week, multicenter, controlled clinical trials of similar design, comparing DIFFERIN Lotion to the lotion vehicle in acne subjects. In Trial 1, 1075 subjects were randomized to DIFFERIN Lotion or vehicle. The median age of these subjects was 16.7 years old and 53.1% were females. At baseline subjects had between 20 to 50 inflammatory lesions and 30 to 100 non-inflammatory lesions. The majority of subjects (91.0%) had a baseline IGA score of 'Moderate'.
In Trial 2, 1066 subjects were randomized to DIFFERIN Lotion or vehicle. The median age of subjects was 16.7 years old and 53.7% were females. At baseline subjects had the same inclusion criteria as in Trial 1 and 95.7% of subjects had a baseline IGA score of 'Moderate'. The outcome of the two trials is presented in Table 3.
Table 3: Clinical Trial Primary Efficacy Results at
|Trial 1||DIFFERIN Lotion
(N = 533)
(N = 542)
|IGA Success||140 (26.3%)||94 (17.3%)|
|Total Lesions: Mean Absolute (Percent) Change||37.9 (51.5%)||26.7 (37.1%)|
|Inflammatory Lesions: Mean Absolute (Percent) Change||14.7 (54.9%)||10.6 (40.3%)|
|Non-inflammatory Lesions: Mean Absolute (Percent) Change||23.2 (49.6%)||16.1 (35.7%)|
|Trial 2||DIFFERIN Lotion (N = 533)||Vehicle Lotion (N = 542)|
|IGA Success||129 (24.1%)||87 (16.4%)|
|Total Lesions: Mean Absolute (Percent) Change||32.4 (44.6%)||23.4 (32.8%)|
|Inflammatory Lesions: Mean Absolute (Percent) Change||12.7 (46.0%)||10.2 (36.9%)|
|Non-inflammatory Lesions: Mean Absolute (Percent) Change||19.6 (43.1%)||13.1 (30.2%)|
Last reviewed on RxList: 5/21/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Differin Lotion .1 Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.